about
Gene therapy in Parkinson's disease: rationale and current statusProtection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's diseaseComparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's DiseaseNeurotrophic factors as a therapeutic target for Parkinson's diseaseIntraoperative intracerebral MRI-guided navigation for accurate targeting in nonhuman primatesAutologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeysActivation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease.AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons.Cell-based therapies for Parkinson's disease: past, present, and futureResponse of aged parkinsonian monkeys to in vivo gene transfer of GDNFBlocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.Nonhuman primate models of Parkinson's disease.Motor neuron trophic factors: therapeutic use in ALS?Positive autoregulation of GDNF levels in the ventral tegmental area mediates long-lasting inhibition of excessive alcohol consumptionCombined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease.RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals.Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's diseaseGDNF gene delivery via a 2-(dimethylamino)ethyl methacrylate based cyclized knot polymer for neuronal cell applications.IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.Treatment of Parkinson's disease with trophic factors.Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeysSIMULATING CONVECTION-ENHANCED DELIVERY IN THE PUTAMEN USING PROBABILISTIC TRACTOGRAPHY.Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.Future of cell and gene therapies for Parkinson's disease.Trophic factor gene therapy for Parkinson's disease.Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.Trophic factors for Parkinson's disease: To live or let die.Gas1 Knockdown Increases the Neuroprotective Effect of Glial Cell-Derived Neurotrophic Factor Against Glutamate-Induced Cell Injury in Human SH-SY5Y Neuroblastoma Cells.Comparison of GDF5 and GDNF as neuroprotective factors for postnatal dopamine neurons in ventral mesencephalic cultures.The proform of glia cell line-derived neurotrophic factor: a potentially biologically active protein.A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.Pericyte-derived glial cell line-derived neurotrophic factor increase the expression of claudin-5 in the blood-brain barrier and the blood-nerve barrier.Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity.Delivering therapy to target: improving the odds for successful drug development.Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration.Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.AAV transduction of dopamine neurons with constitutively active Rheb protects from neurodegeneration and mediates axon regrowth.Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases.
P2860
Q22241423-B410BD2C-7A9D-4D2A-AD2E-51C94FB660E2Q27302176-31D0C242-5B9E-42E8-B839-84953E6EF64EQ27320553-D01494E8-F666-4A7D-B16C-C510EBE4E93CQ28273071-CFDA6364-D804-4649-99B5-8561A4AA7ED6Q28732112-68D35F89-C9C7-452C-B875-A761C069A07FQ30581632-C5AD673B-C587-4326-887C-1FCF3CC78D65Q33517934-807F4DAC-C15E-4702-A718-D972971AA478Q33791830-0B418A61-1D01-48D5-87E6-667542B1024EQ33818127-A2328AD1-BA72-4AE8-9C25-06C38A5AC7E8Q34339833-E414DAF5-3866-48FD-9919-CCF488EB950DQ34345195-CD6232E8-D5F8-4D8A-84F8-9CFFBA9AE44FQ34503671-82631B54-385F-4027-921A-9EB7C58BA36AQ34665820-2F88454B-6CB4-4A90-9987-2B2B82ECB9ECQ35027903-B1DABF4F-820F-4427-BEC7-642B27CB59BDQ35660521-6D6C3E1C-80C9-46AB-8E17-33D819F7EEC9Q35822548-9B6F7FCA-41F2-4E70-B10F-927ADED606FEQ36289043-0B319ACB-0130-4902-A58C-BAF34C066930Q36713101-7808F53D-9145-4B82-BC8E-84C2225998A9Q36778996-8767D0C5-5D72-4782-A353-01C087FFB646Q36971278-1E512780-E802-4986-8BCE-DB69E8467556Q37131259-4E1F7AB1-BEB2-403B-9B01-FC16A2A23F23Q37187908-7AAFCE70-F32B-4895-A814-DC17255A4DB9Q37370495-6F3E82CC-7B27-4EEF-AE46-CF9E24B68218Q37399627-F867A9E7-A3BF-4EE2-9D45-19AC8FFFD35DQ37582397-6BD46B35-0999-435A-A27E-D2C2ABCAB18BQ37696495-604712FF-862C-4824-AFD8-D24662766F63Q38079792-C1194DB1-3BF4-4358-838A-A450ED2BE1ECQ38194531-2DA2209A-62EE-4050-9B3A-3A6D23E8FF8BQ38697393-B1B0EC4E-F6D8-4841-8D4F-6C1DEBEC683AQ38848864-DFC4DD5E-6BB9-4A3A-89C1-F28A826C52A0Q38986034-8758D89E-214F-460E-9999-403DB5F08EB3Q39112142-93231B9D-A14F-451E-BBE9-8760E371B75CQ39278446-CC5F80E8-E270-49AC-958C-A1FA82A0A3B4Q39457264-A6D6E9D9-2E36-4BB0-B860-11BC7F62E5DFQ39463659-C6BB6812-BC90-46C4-9B6C-8F0734C2538DQ39610770-B35FCFE7-8AB1-444B-A33B-C8BC9AABA788Q39634067-1362868C-98E6-48A4-A566-57953245F3A6Q39782948-F4038A27-8514-4301-A180-5BB470515243Q41020743-E0CF8023-361E-4572-851B-6E30D2CBBF32Q41195395-B6EF951C-ECD0-406B-A7D3-EC652BEA462D
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Crossroads in GDNF therapy for Parkinson's disease
@ast
Crossroads in GDNF therapy for Parkinson's disease
@en
Crossroads in GDNF therapy for Parkinson's disease
@nl
type
label
Crossroads in GDNF therapy for Parkinson's disease
@ast
Crossroads in GDNF therapy for Parkinson's disease
@en
Crossroads in GDNF therapy for Parkinson's disease
@nl
prefLabel
Crossroads in GDNF therapy for Parkinson's disease
@ast
Crossroads in GDNF therapy for Parkinson's disease
@en
Crossroads in GDNF therapy for Parkinson's disease
@nl
P2093
P356
P1433
P1476
Crossroads in GDNF therapy for Parkinson's disease
@en
P2093
Brian K Fiske
Clive N Svendsen
J William Langston
Todd B Sherer
P304
P356
10.1002/MDS.20861
P407
P50
P577
2006-02-01T00:00:00Z